Objective To explore the feasibility and advantages of transvaginal myomectomy(TVM).Methods A total of 65 patients with uterine myoma were treated with TVM from August 2002 to August 2004.The myomectomy was performed through a vaginal incision,which was transversely made through anterior or posterior fornix of the vagina.The uterus was exposed outside the incision with a pulling suture.The muscular layer covering the myoma was incised and the myoma was removed.Then the incisions of the uterus and vagina were closed respectively by using absorbable sutures.Results The TVM was successfully completed in all the 65 patients.The surgical time was 25~140 min(mean,56 ?19 min),the postoperative bleeding amount was 60~650 ml(mean,170?45 ml),and the length of hospital stay after operation,2~5 d.A follow-up was carried out for 2~12 months(mean,3.6?2 months) in 58 patients.The flow of menstrual cycle recovered to normal levels in 40 patients and was less than normal levels in 2 patients.Pressure symptoms of adjacent organs disappeared,and no residual tumors were detected on B-ultrasonography.Conclusions Transvaginal myomectomy is a safe and reliable procedure with little invasion and quick recovery.

Objective To detect the expression of gonadotropin-releasing hormone (GnRH) in cervical cancer and to explore the correlation.Methods A total of 68 patients with cervical squamous cell carcinoma and 45 patients with chronic cervicitis were selected.Immunohistochemistry and hybridization in situ were used to detect the expression of GnRH in cancer tissue and cervicitis.Protein and nucleic acid level were observed in patients with GnRH.Results In 45 patients with cervicitis, both GnRH and GnRH mRNA expressions were negative in cervical epithelial tissue, while in 68 cases of cervical squamous cell cancer, the positive expression of GnRH in cancer tissues was 82.36%, and positive expression rate of GnRH mRNA was 64.71%.There were significant differences in levels of GnRH and GnRH mRNA between patients with cervicitis and cervical squamous cell carcinoma (P<0.05).The qualitative expression rates of GnRH in different clinical stages of cervical cancer were 55.56% of Ib, 87.10% of IIa and 100% of IIb, and qualitative expression rates of GnRH mRNA in different clinical stages of cervical cancer were 38.89% of Ib, 70.97% of IIa and 84.21% of IIb.There were significant differences in GnRH and GnRH mRNA levels between patients with different clinical stages of cervical cancer (P<0.05).Conclusion There is a high level of gonadotropin-releasing hormone in cervical cancer, which may be involved in the development of cancer cells.

Objective To detect the expression of gonadotropin-releasing hormone (GnRH) in cervical cancer and to explore the correlation.Methods A total of 68 patients with cervical squamous cell carcinoma and 45 patients with chronic cervicitis were selected.Immunohistochemistry and hybridization in situ were used to detect the expression of GnRH in cancer tissue and cervicitis.Protein and nucleic acid level were observed in patients with GnRH.Results In 45 patients with cervicitis, both GnRH and GnRH mRNA expressions were negative in cervical epithelial tissue, while in 68 cases of cervical squamous cell cancer, the positive expression of GnRH in cancer tissues was 82.36%, and positive expression rate of GnRH mRNA was 64.71%.There were significant differences in levels of GnRH and GnRH mRNA between patients with cervicitis and cervical squamous cell carcinoma (P<0.05).The qualitative expression rates of GnRH in different clinical stages of cervical cancer were 55.56% of Ib, 87.10% of IIa and 100% of IIb, and qualitative expression rates of GnRH mRNA in different clinical stages of cervical cancer were 38.89% of Ib, 70.97% of IIa and 84.21% of IIb.There were significant differences in GnRH and GnRH mRNA levels between patients with different clinical stages of cervical cancer (P<0.05).Conclusion There is a high level of gonadotropin-releasing hormone in cervical cancer, which may be involved in the development of cancer cells.